A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

NCT03959488 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

925

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: MEDI8897
DRUG: Palivizumab

Sponsor

AstraZeneca